Tuberculosis and Respiratory Diseases

  • 제71권4호
  • /
  • Pages.245-248
  • /
  • 2011
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

호흡기내과 의사를 위한 정맥혈전증 리뷰

Clinical Year in Review of Venous Thromboembolism

  • 김양기 (순천향대학교 의과대학 내과학교실)
  • Kim, Yang-Ki (Division of Respiratory and Allergy Medicine, Department of Internal Medicine, Soonchunhyang University College of Medicine)
  • 투고 : 2011.05.23
  • 심사 : 2011.05.23
  • 발행 : 2011.10.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Venous thromboembolism represents as an obstruction of a vein by a blood clot in the blood stream. The most common manifestations of venous thromboembolism (VTE) are pulmonary embolism and deep vein thrombosis (DVT) of the lower extremity. This article reviews the recent advances in this spectrum and introduces new drugs that will be used in venous thromboembolism in the near future.

키워드

참고문헌

  1. Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011;9:85-91. https://doi.org/10.1111/j.1538-7836.2010.04108.x
  2. Sweetland S, Green J, Liu B, Berrington de Gonzalez A, Canonico M, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2009;339:b4583. https://doi.org/10.1136/bmj.b4583
  3. Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010;8:101-6. https://doi.org/10.1111/j.1538-7836.2009.03652.x
  4. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):454S-545S. https://doi.org/10.1378/chest.08-0658
  5. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.
  6. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010;153:523-31. https://doi.org/10.7326/0003-4819-153-8-201010190-00009
  7. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780-9. https://doi.org/10.1056/NEJMoa054444
  8. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008;149:481-90, W94. https://doi.org/10.7326/0003-4819-149-7-200810070-00008
  9. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52. https://doi.org/10.1056/NEJMoa0906598
  10. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510. https://doi.org/10.1056/NEJMoa1007903

피인용 문헌

  1. Recurrent Acute Pulmonary Embolism Associated With Protein S Deficiency vol.17, pp.1, 2011, https://doi.org/10.4235/jkgs.2013.17.1.55